Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.
In a trial of patients receiving nivolumab plus ipilimumab or a placebo plus ipilimumab, survival in patients who discontinued use due to toxicity was observed.
Using a web application developed by French researchers may help clinicans to better manage follow-up for patients with lung cancer.
Patients with metastatic castrate resistant prostate cancer treated with enzalutamide may experience central nervous system adverse events.
Representatives from American Society of Clinical Oncology and the European CanCer Organisation discussed strategies for delivering more value-based care.
Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.
Clinical trial results have shown that patients with advanced bladder cancer may have their tumor burden reduced through treatment with nivolumab.
In this session at the American Society of Clinical Oncology Annual Meeting, presenters discussed the benefits of measuring the quality of care through the Quality Oncology Practice Initiative and how ASCO's Value Framework is trying to transform care delivery.
At the American Society of Clinical Oncology Annual Meeting, presenters provided insight and reccomendations on what will be the new reimbursement model under MACRA.
Using biomarkers to guide treatment in clinical trials may yield higher response rates than similar drugs not guided by biomarkers, according to an abstract presented at the American Society of Clinical Oncology Annual Meeting (June 3-7, 2016; Chicago, IL).